Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$29.80 +0.7%	$28.66	$23.42 ▼ $62.58	$1.73B	0.77	695,398 shs	440,665 shs
BBIO BridgeBio Pharma	$33.34 +1.1%	$34.50	$21.62 ▼ $39.54	$6.33B	1.15	2.45 million shs	2.05 million shs
BPMC Blueprint Medicines	$101.50 +1.2%	$90.77	$73.04 ▼ $121.90	$6.56B	0.83	781,410 shs	353,347 shs
ELAN Elanco Animal Health	$12.66 -0.1%	$10.34	$8.02 ▼ $18.80	$6.29B	1.49	5.07 million shs	4.74 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+2.12%	+1.85%	-15.38%	-10.89%
BBIO BridgeBio Pharma	0.00%	-1.48%	-7.29%	-9.53%	+13.91%
BPMC Blueprint Medicines	0.00%	-0.19%	+17.90%	+10.03%	-1.18%
ELAN Elanco Animal Health	0.00%	-2.10%	+34.00%	+14.95%	-25.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	3.9505 of 5 stars	3.3	1.0	4.2	2.9	0.8	1.9
BBIO BridgeBio Pharma	4.5892 of 5 stars	4.5	2.0	3.9	3.3	3.3	0.6
BPMC Blueprint Medicines	1.7317 of 5 stars	3.4	1.0	0.0	3.0	0.8	0.6
ELAN Elanco Animal Health	3.2167 of 5 stars	3.2	2.0	0.3	3.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.00	87.92% Upside
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	71.24% Upside
BPMC Blueprint Medicines	2.83	Moderate Buy	$126.56	24.69% Upside
ELAN Elanco Animal Health	2.43	Hold	$15.17	19.77% Upside

Current Analyst Ratings Breakdown

Latest AGIO, ELAN, BPMC, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
5/8/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
5/2/2025	BPMC Blueprint Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00
5/1/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$128.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/28/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$133.00 ➝ $130.00
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	46.60	N/A	N/A	$27.02 per share	1.10
BBIO BridgeBio Pharma	$127.42M	49.69	N/A	N/A	($7.71) per share	-4.32
BPMC Blueprint Medicines	$562.12M	11.66	N/A	N/A	$4.67 per share	21.73
ELAN Elanco Animal Health	$4.43B	1.42	$2.62 per share	4.84	$12.63 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	2.63	N/A	N/A	1,845.92%	-2.51%	-2.26%	8/7/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	8/7/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	156.15	N/A	-13.19%	-77.49%	-20.84%	8/7/2025 (Estimated)
ELAN Elanco Animal Health	-$1.23B	$0.74	31.66	14.23	2.50	4.60%	6.78%	3.03%	N/A

Latest AGIO, ELAN, BPMC, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
2/25/2025	Q4 2024	ELAN Elanco Animal Health	$0.15	$0.14	-$0.01	-$0.02	$1.01 billion	$1.02 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
BBIO BridgeBio Pharma	N/A	4.67	4.67
BPMC Blueprint Medicines	1.15	2.85	2.80
ELAN Elanco Animal Health	0.66	2.55	1.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
ELAN Elanco Animal Health	97.48%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
ELAN Elanco Animal Health	0.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
ELAN Elanco Animal Health	9,800	496.65 million	491.54 million	Optionable

AGIO, ELAN, BPMC, and BBIO Headlines

Recent News About These Companies

Lazard Asset Management LLC Purchases 25,109 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 25 at 3:38 AM | marketbeat.com

BNP Paribas Financial Markets Sells 204,974 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 25 at 3:19 AM | marketbeat.com

Sherbrooke Park Advisers LLC Sells 38,456 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 23 at 4:54 AM | marketbeat.com

Twinbeech Capital LP Increases Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

May 22 at 5:34 AM | marketbeat.com

Bank of America Corp DE Sells 430,146 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 22 at 3:36 AM | marketbeat.com

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Teza Capital Management LLC

May 21, 2025 | marketbeat.com

Cresset Asset Management LLC Reduces Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

May 21, 2025 | marketbeat.com

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Tang Capital Management LLC

May 20, 2025 | marketbeat.com

Focus Partners Wealth Acquires 105,220 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 20, 2025 | marketbeat.com

Stifel Nicolaus Increases Elanco Animal Health (NYSE:ELAN) Price Target to $16.00

May 20, 2025 | americanbankingnews.com

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Sapience Investments LLC

May 19, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

May 19, 2025 | marketbeat.com

Shapiro Capital Management LLC Has $149.64 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

May 18, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires Shares of 80,899 Elanco Animal Health Incorporated (NYSE:ELAN)

May 18, 2025 | marketbeat.com

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by D. E. Shaw & Co. Inc.

May 18, 2025 | marketbeat.com

Deutsche Bank AG Grows Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

May 18, 2025 | marketbeat.com

Comerica Bank Acquires 26,517 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

May 18, 2025 | marketbeat.com

Purdue supplements construction management curriculum with hands-on training

May 17, 2025 | ibj.com

Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Hold" from Brokerages

May 17, 2025 | marketbeat.com

Elanco to Participate in the Upcoming Investor Conferences

May 16, 2025 | prnewswire.com

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Gotham Asset Management LLC

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
3 Undervalued Stocks Wall Street Is Getting Wrong
By Gabriel Osorio-Mazilli | May 12, 2025
View 3 Undervalued Stocks Wall Street Is Getting Wrong
Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?
By Jeffrey Neal Johnson | May 8, 2025
View Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?

AGIO, ELAN, BPMC, and BBIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$29.80 +0.21 (+0.71%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$29.79 -0.01 (-0.03%)

As of 05/23/2025 05:32 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

BridgeBio Pharma NASDAQ:BBIO

$33.34 +0.37 (+1.12%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$34.65 +1.31 (+3.93%)

As of 05/23/2025 07:48 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$101.50 +1.16 (+1.16%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$105.00 +3.50 (+3.45%)

As of 05/23/2025 05:08 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health NYSE:ELAN

$12.66 -0.01 (-0.06%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$12.50 -0.17 (-1.33%)

As of 05/23/2025 07:15 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time